Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock

Key Points

• CEO insider buying: Ivor Elrifi purchased 83,807 Tiziana Life Sciences shares at an average price of $0.97, worth about $81,293. He also bought 904,616 shares in two other recent transactions, bringing his holdings to 4.56 million shares.
• Stock performance: TLSA shares rose 3.5% to $1.02, with trading volume of 434,962 shares. The stock remains below its 50-day and 200-day moving averages and has traded between $0.87 and $2.53 over the past year.
• Analyst sentiment remains cautious: Ratings include one Hold and one Sell, resulting in a consensus “Reduce” rating. Tiziana is a clinical-stage biotechnology company developing therapies for oncology, immunology and infectious diseases.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) CEO Ivor Elrifi purchased 83,807 shares of the stock in a transaction dated Tuesday, August 4th. The shares were purchased at an average price of $0.97 per share, with a total value of $81,292.79. Following the completion of the acquisition, the chief executive officer owned 4,556,068 shares of the company's stock, valued at approximately $4,419,385.96. This represents a 1.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi bought 237,616 shares of Tiziana Life Sciences stock. The stock was purchased at an average cost of $1.00 per share, with a total value of $237,616.00.
• On Monday, August 3rd, Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock. The stock was acquired at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Trading Up 3.5%

Shares of Tiziana Life Sciences stock traded up $0.04 during trading hours on Thursday, reaching $1.02. 434,962 shares of the company's stock were exchanged, compared to its average volume of 240,434. Tiziana Life Sciences Ltd has a 52-week low of $0.87 and a 52-week high of $2.53. The company has a fifty day moving average of $1.15 and a 200-day moving average of $1.30.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on TLSA shares. Wall Street Zen downgraded Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, April 18th. Zacks Research upgraded Tiziana Life Sciences to a "hold" rating in a report on Tuesday, July 14th. Finally, Weiss Ratings downgraded shares of Tiziana Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Tiziana Life Sciences presently has a consensus rating of "Reduce".

Institutional Trading of Tiziana Life Sciences

Institutional investors have recently made changes to their positions in the stock. Bison Wealth LLC acquired a new position in Tiziana Life Sciences in the fourth quarter valued at $30,000. Zhang Financial LLC grew its position in Tiziana Life Sciences by 18.6% during the fourth quarter. Zhang Financial LLC now owns 99,900 shares of the company's stock valued at $149,000 after acquiring an additional 15,700 shares during the period. Rachor Investment Advisory Services LLC acquired a new stake in Tiziana Life Sciences during the fourth quarter worth about $25,000. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences during the fourth quarter worth about $59,000. Finally, Marshall Wace LLP raised its holdings in shares of Tiziana Life Sciences by 5.2% in the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company's stock worth $420,000 after purchasing an additional 14,005 shares during the period.

About Tiziana Life Sciences

Tiziana Life Sciences plc NASDAQ: TLSA is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source